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Abstract 
To accelerate the development of novel vaccines for schistosomiasis, we set out to develop a human 
model for Schistosoma mansoni infection in healthy volunteers. During natural infections female 
schistosomes produce eggs that give rise to morbidity. Therefore, we produced single sex, male 
Schistosoma mansoni cercariae for human infection without egg production and associated 
pathology. Cercariae were produced in their intermediate snail hosts in accordance with the 
principles of Good Manufacturing Practice. The application of GMP principles to an unconventional 
production process is a showcase for the controlled production of complex live challenge material in 
the EU or under FDA guidance. 
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Article’s main point 
To accelerate the development of novel vaccines and drugs, a controlled human infection model was 
established for Schistosoma mansoni with the application of GMP principles to the unconventional 
production process for cercariae.  
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Background 
Schistosomiasis ranks amongst the leading neglected tropical diseases in terms of disability–adjusted 
life years with roughly 252 million people infected worldwide[1]. Schistosoma mansoni and 
Schistosoma haematobium are responsible for the majority of cases[2]. Morbidity in schistosomiasis 
is caused by the inflammatory response to tissue-deposited eggs, which induce granulomas and 
fibrosis, that can lead to portal hypertension or bladder cancer[2]. 
Current schistosomiasis control programs rely on the mass administration of praziquantel, but 
transmission of schistosomes persists primarily due to high reinfection rates[3]. Alternative tools to 
break transmission and eliminate schistosomiasis are urgently needed. The development of a highly 
efficacious vaccine would be a major asset to schistosomiasis control programs. 
Vaccination studies in mice and non-human primates prove that immunity to schistosomes can be 
induced by repeated exposure to radiation-attenuated cercariae[4, 5]. Based on such landmark 
studies, stage-specific antigens have been identified which reduce worm burden by >40%[6]. 
Currently there are four vaccine candidates in clinical stage of development (Sh28GST, Sm-TSP-2, 
Sm14 and Smp80)[6, 7]. Typically, these vaccine candidates undergo phase 1 testing for safety after 
which efficacy needs to be demonstrated in large-scale field trials in endemic areas. To obtain an 
estimate of the vaccine induced protective efficacy, trials of long duration and/or large population 
size are necessary.  
To decrease the risk of downstream efficacy failure, healthy volunteers have been deliberately 
exposed to infectious agents to test malaria, dengue and influenza vaccines[8]. Such controlled 
human infection (CHI) trials provided early efficacy estimates which were used to guide further 
clinical development. The availability of a CHI model for schistosome infection could revolutionize 
the development of schistosomiasis vaccines.  
To ensure the safety of participants in a human schistosome infection trial, a challenge inoculum 
should be available which complies with regulatory requirements for human use and cannot induce 
eggs-associated morbidity. We therefore took an important conceptual step to produce single sex, 
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male, schistosome cercariae in accordance with Good Manufacturing Practice (GMP) principles. The 
production of live parasites, which comply with the highly demanding regulatory environment in 
place currently, is a showcase for the production of complex live challenge material in the EU or 
under FDA guidance.  
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Methods 
Production principles 
Manufacturing of single sex cercariae for the purpose of controlled human schistosome infections 
was performed within the quality control and quality assurance system of the Interdivisional GMP 
facility of the Leiden University Medical Center (IGFL, LUMC). The product was characterized as 
an auxiliary medicinal product (AxMP, Regulation EU 536/2014), or previously a non-
investigational medicinal product according to the definition of the EU clinical trial directive 
2001/20/EC. The principles of GMP as outlined in the EC directive 2003/94/EC were applied in 
the production process wherever possible. Cercariae were produced in a biosafety level 3 (DM3) 
laboratory environment with humidity, temperature and pressure control. The production 
process (figure 1) was standardized in 34 standard operating procedures, which were kept in the 
institutional document management system. A product dossier was created according to section 2.7 
of EC CT-1 guideline (2010/C 82/01) for pharmacological products. All disposables, reagents, 
solvents, culture media and starting materials were released by the person responsible for Quality 
Control (QC) and the Qualified Person (QP) specific for advanced cell therapy medicinal products 
(ATMP). All manufacturing steps and batch numbers of all used materials were entered and logged 
real time in a GMP compliant digital database using a portable tablet. The use of a tablet facilitated 
communication between manufacturers and QC officers without breaching hygienic procedures 
established for containment of the DM3 environment. A separate read-only account was held by the 
QC officer and the QP. Monitored data was locked for editing by the QP. All QC testing was 
independently analyzed by the QC, thereafter the product was released by the QP. 
 
Origin of snails and parasites 
The Schistosoma mansoni (Sm) Puerto Rico strain used for the production was obtained together 
with their Biomphalaria glabrata snail hosts by Prof. C.F.A. Bruijning in 1955[Prof. A.M. Deelder, 
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personal communication]. This isolate has been maintained in laboratory culture in the LUMC by 
routine passaging of the schistosomes through laboratory hamsters and/or mice as definitive host 
and laboratory cultured Biomphalaria glabrata snails as intermediate host. Adult worms were 
genetically characterised to confirm its origin (see Supplement).  
 
Production of cercariae 
Sm miracidia were obtained by light-induced hatching of Sm eggs isolated from an infected 
hamster[9]. After single-miracidium infection[10], Biomphalaria glabrata snails of the same batch 
(i.e. infection day) were housed and labelled individually and shed after 5 weeks. Cercariae were 
counted and viability was determined by calculating percentage moving.  
 
Identity and sex confirmation  
Identity and sex of cercariae were determined by a purpose-made multiplex real-time PCR targeting 
Schistosoma-specific ITS2 sequences[11] as well as the Sm W1 repeat[12] (see Supplement). The W1 
copy number is much lower in male as compared to female schistosomes[13]. Using DNA of 
duplicate cercaria samples unequivocally resulted in an ITS2 cycle threshold (Ct) between 15 and 30. 
Sex was determined by the difference in Ct between W1 and ITS2: >10ΔCt for males, <4ΔCt for 
females. Sensitivity of the qPCR was confirmed in samples containing only one cercaria (mean ITS2 
Ct: 23). To validate the PCR, single sex cercaria samples were sex confirmed by assessment of the 
morphology of adult worms after hamster infection.  
 
Bioburden testing  
Shed waters were tested for bioburden at the ISO-15189 certified clinical medical microbiology 
laboratory of the LUMC (see Supplement). Aeromonas spp, Staphylococcus aureus, β-hemolytic 
streptococci and Pseudomonas aeruginosa were defined as pathogenic bacteria potentially 
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causing skin infections upon transfer with cercariae. Cultures were optimized for detection of 
these bacteria. To reduce bioburden, snails were kept at 2 mg/L ciprofloxacin and 4 mg/L 
gentamicin for 24 hours before clinical use.  
One week before use, bioburden of shed water was assessed before and after antibiotic treatment. 
After shedding for clinical use, cercariae were counted, viability was recorded and doses were 
prepared by two persons separately.   
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Results 
Preclinical production data 
In preparation for the production of clinical trial material, 24 preclinical batches of single-miracidium 
infected snails were produced, averaging 12 snails per batch. Of those 294 snails, 246 (84%) were 
still alive at week 5. In total 47 snails (19%) shed cercariae, of which 25 (53%) were male (figure 2A). 
Viability of cercariae was always very high (>90% in all batches), but the number of cercariae per 
shed varied considerably per snail and over time. At week 5 snails shed an approximate number of 
3500 cercariae (geometric mean (GM) 3416, 95%CI 2386-4889), decreasing to 1261 at week 7 (95%CI 
704-2259, Mann-Whitney P<0.0001, figure 2B). The number of cercariae per shed was not affected 
by the cercarial sex (Mann-Whitney P=0.6, figure 2C). Based on these data, cercariae of shed 2 were 
preferably selected for clinical use. 
 
Sex identification by qPCR  
Sex and identity were unequivocally confirmed in all cercarial samples (figure 2D). Samples obtained 
from snails shedding mixed male and female cercariae always showed ΔCt similar to female only 
cercariae (ΔCt W1-ITS2 min 2.83, max 4.88 for mixed, ΔCt W1-ITS2 min 2.24, max 3.11 for females). 
Samples containing only male cercariae always showed different ΔCt (min 11.83, max undetectable). 
Thus, the >6ΔCt difference between male and female cercarial samples ensured that male sex could 
always be confirmed with certainty.  
 
Bioburden 
All samples tested for bioburden were found to contain Aeromonas veronii biovar sobria sensitive 
for ciprofloxacine, gentamicin and co-trimoxazole. No other pathogenic bacteria were cultured. 
Because Aeromonas spp. are incidentally reported as causative agents of skin infections, production 
snails were pre-treated with antibiotics before clinical use of cercariae. After this treatment all 
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samples were free of Aeromonas spp. After antibiotic treatment waterborne bacteria such as 
Chryseobacterium and Stenotrophomonas maltophilia persisted, which are not known to cause 
infections in healthy volunteers. 
 
In-process testing and release 
Sm miracidia and hamsters were defined as starting materials and were released by the QC. Based 
on the critical steps in the production process, three in-process tests were defined: 1) confirmation 
of single-miracidium infection of snails by a second person, 2) daily examination of snail viability, 3) 
number and viability of cercariae after first shed (i.e. >100 and >90%). 
A two-step release procedure was established with a conditional release procedure immediately 
after dose preparation, followed by a final release procedure when bioburden tests were completed 
three days later. Criteria for conditional release were based on 1) absence of potentially pathogenic 
bacteria after antibiotic treatment of two snails from the same batch; 2) identity confirmation of 
cercarial species and male sex by qPCR, 3) absence of potentially pathogenic bacteria resistant to 
ciprofloxacine and gentamicin, 4) presence of >100 cercariae with >90% viability.  
Shelf life of the product at 28°C was determined at 2 hours, when 96% (95%CI 91-100%) of cercariae 
were confirmed viable by microscopy. At 4 hours viability was more variable (95%CI 81-100%, mean 
96%) and at 24 hours viability had dropped to 14% (95%CI 4-24%).  
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Figure legends 
 
Figure 1: Schematic representation of the production process 
 
Figure 2: Percentages of uninfected, dead and infected Biomphalaria glabrata snails with either 
male or female cercariae after single-miracidium infection (A), number of cercariae produced by 
each snail for each weekly shed starting from week 5 after infection (B) and number of male or 
female cercariae from shed 1 or 2 (C). Results from sex-specific PCR, shown as the difference in Ct-
value between the ITS2 gene and W1 repeat, in 47 cercarial samples from preclinical production (D).  
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Discussion 
In summary, we were able to establish a rigorous production process for male Schistosoma mansoni 
cercaria, complying with current regulatory standards for human use. Despite the complex, 
unconventional production process that includes a snail host, production was in accordance with the 
principles of GMP with clearly defined release criteria which were supervised by a QC and QP ATMP. 
CHI trials are increasingly used for the down selection of novel drugs or vaccines[8]. However, 
specific guidelines regarding the production of challenge material are often lacking. Whereas the 
FDA states stage-appropriate GMP is required, EMA guidelines for auxiliary medicinal products state 
that full GMP may not be required but deviations must be justified (Clinical trials, Directive 
2001/20/EC, NIMPs)[14]. In this specific case, the production process in snails is exceptional and 
requires thorough risk analysis, intense collaboration of pharmacists, clinicians and technicians. 
Paramount to the safety of volunteers in a controlled human schistosome trial is the ability to 
determine cercaria sex, so egg-induced pathology cannot occur. To this end, we have developed 
technologies and procedures to ensure unique identification and tracking of individual snails.  
In order to confirm identity and sex of cercariae, we established a sensitive and specific multiplex 
real-time PCR. We confirmed high variability in the copy numbers of the female-specific W1 repeat 
in male cercaria, corroborating previous data[13]. Nevertheless male cercariae could be confidently 
distinguished from female or “mixed” cercarial samples, based on a large difference in Ct between 
male and female/mixed samples. Should the production of female cercariae be necessary in the 
future, multiple individual cercariae from one snail should be tested to confirm sex. 
We have performed full characterization of the bioburden associated with the snail microbiome. We 
focused on excluding microbiological contaminants which might cause a risk of adverse events when 
applied to the cercaria-penetrated skin. We believe that the current remaining non-pathogenic 
bioburden does not pose any risk for volunteers. In addition, the rearing of sterile snails has not 
been reported previously and might be biologically challenging given the increasing evidence that 
the microbiome is essential for the healthy being of particularly non-vertebrates[15].  
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Both the Biomphalaria glabrata snails as well as the Sm parasites have been kept in the laboratory 
for more than 60 years. Although the origin of the isolates lacked a full historical paper trail, the 
main advantage of such an old and highly established laboratory culture is the naivety to 
praziquantel, excluding possible resistance. Nevertheless, for clinical use, extensive follow-up is 
needed to ensure full cure after praziquantel administration. We performed genotyping to confirm 
the parasite strain as S. mansoni from Puerto Rico. Future efforts will focus on establishing a master 
and working bank of parasites, although cryopreservation of schistosome cercariae, miracidia or 
eggs has not been previously performed and may be challenging.  
In conclusion, through an interdisciplinary approach, we were able to achieve highly controlled 
production of viable male Schistosoma mansoni cercariae. Following these efforts, the next steps will 
be the use of cercariae for infection of healthy volunteers in a proof-of-concept clinical trial, aiming 
to find a safe and infectious dose. Establishing a controlled human infection model for 
schistosomiasis will be a game-changing step to accelerate the development of novel vaccines and 
drugs for this devastating disease.  
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Supplement 
Origin of parasites 
Genomic DNA was extracted from pooled worms using the DNeasy tissue kit (QIAgen) according to 
the manufacturer’s protocol. The mitochondrial cox1 region was PCR amplified and sequenced as 
described in Webster et al., 2013 [1]. The sequences were compared to the S. mansoni cox1 
database to find the closest identity, which was a 99% match to Genbank Accession: HE601612 
(Mitochondrial genome of S. mansoni Puerto Rico).   
Sex-identity Schistosoma multiplex qPCR  
DNA from at least 50 cercariae was isolated with the QIAamp DNA mini kit spin columns (QIAgen, 
Hilden, Germany) and diluted 1:100. The multiplex PCR amplified a 77-bp fragment from the 
Schistosoma-specific ITS2 sequences (with primers Ssp48F, Ssp124R and probe Ssp78T) [2] and a 
121-basepair fragment from the female specific Schistosoma mansoni W1 repeat (with primers 
SmW1-238F, SmW1-358R and probe SmW1-291T (Biolegio, Netherlands)) [3]. Amplification was 
performed in 20 µl PCR mix and 5 µl of cercarial DNA. Table 1 shows the concentrations of the PCR 
mix used with the sequences of all primers and double-labelled probes. The CFX real-time detection 
system (Bio-Rad laboratories) was used with amplification program of 15 min at 95°C followed by 50 
cycles of 15s at 95°C, 30s at 60°C, and 30s at 72°C. Negative and positive (mixed, male and female) 
control samples were included.  
Table 1: PCR mix and primer/probe sequences of the sex-identity Schistosoma multiplex PCR 
Components Concentration Per sample  Sequence 
H20  2,73  
MgCl2   25 mM 3,50  
BSA       5 mg/ml 0,50  
Primer Ssp48F 25 µM 0,06 5’-GGTCTAGATGACTTGATTGAGATGCT-3’ 
Primer Ssp124R 25 µM 0,06 5’-TCCCGAGCGTGTATAATGTCATTA-3’ 
Probe  Ssp78T 10 µM 0,13 FAM-5’-TGGGTTGTGCTCGAGTCGTGGC-3’-BHQ1 
Primer SmW1-238F 25 µM 0,20 5’-TGTTTGTGGATGCGATGGTG-3’ 
Primer SmW1-358R 25 µM 0,20 5’-TGTGCACAAGCAACGATTCC-3’ 
Probe  SmW1-291T 10 µM 0,13 YAK-5’-GCGATGATGCATTAGGGTGTGTGGT-3’-BHQ1 
HotStarTaq Master Mix   12,50  
Bioburden testing 
Shed water was plated on Trypcase Soy Agar with 5% sheep blood, Cystine lactose electrolyte 
deficient agar, Columbia agar with colistin and nalidixic acid, Xylose Lysine Desoxycholaat Agar 
(Biomerieux, Marcy-l'Étoile, France) and Cefsulodin Irgasan Novobiocine agar (Media Products, 
Groningen, The Netherlands) and incubated aerobically for 48 hours at 35°C. Plates were 
checked daily for the growth of bacteria. Identification was performed by MALDI TOF mass 
spectrometry (MALDI Biotyper, Bruker Daltonik GmbH, Bremen, Germany) and susceptibility 
testing in a Vitek 2 instrument (Biomerieux) or, in case of streptococci by disk diffusion (Oxoid, 
Thermofisher, Landsmeer, The Netherlands). 
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